Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.

doi:10.3109/10428194.2013.828352

Article

Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.

Leukemia & lymphoma - 1 May 2014

Corbi Fernanda C, de Oliveira Mariana Bleker, Morelli Vania M, Han Sang W, Renauld Jean-Christophe, Knoops Laurent, Colleoni Gisele W B

Abstract excerpt

Abstract Considering the recent impact of tyrosine kinase inhibitors in the treatment of myeloproliferative disorders carrying a recurrent JAK2 mutation not identified in multiple myeloma (MM), this study aimed to search for mutations in kinase and pseudokinase domains of the JAK1 gene in an attempt to define any critical and recurring change that can be used as a therapeutic target. We obtained CD138 + purified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1.

Abstract excerpt

Topics

Related research